ABSTRACT
AIMS: A new polypeptide, PDTLN1, derived from the human Talin-1 protein, which is highly expressed in both myocardial tissue and maternal peripheral blood of aborted fetuses with congenital heart disease (CHD). However, its role in cardiac developmental disorders has not been disclosed till now. In the present study, we aim to assess the functions of PDTLN1 in heart development of zebrafish and cellular viability, proliferation, and apoptosis of P19 cells. MAIN METHODS: Cellular viability was assessed by Cell Counting Kit-8, the EdU Kit was used to evaluate cellular proliferation, and apoptosic rate of P19 was examined using FITC Annexin-V staining followed by flow cytometry. The zebrafish embryos were divided into three groups: PEP group and NC group were microinjected with polypeptides, WT group without any intervention. The protein expression of PI3K/AKT were evaluated by western blotting. KEY FINDINGS: PDTLN1 could suppress the proliferation, and facilitate apoptosis. PDTLN1 caused abnormal heart development of zebrafish embryos and the PDTLN1 (50 µM)-injected group showed an aberrant expression pattern of vmhc, amhc and cmlc2. Compared to the CTL group and SC79 group of P19 cells, the PDTLN1 group had a lower phosphorylated PI3K/AKT proteins level, decreased cellular viability and lower proliferation activity. SIGNIFICANCE: PDTLN1 caused cardiac developmental defects in zebrafish, inhibited cellular viability, proliferation, and promoted apoptosis of P19 cells via suppressing the PI3K/AKT signaling pathway. Our findings provide a fresh perspective on the functional mechanism of human-derived peptides and may promote novel diagnostic biomarkers detection and therapeutic targets in CHD.
Subject(s)
Apoptosis/drug effects , Heart Diseases , Peptides , Phosphatidylinositol 3-Kinases/metabolism , Proto-Oncogene Proteins c-akt/metabolism , Signal Transduction/drug effects , Talin/chemistry , Zebrafish Proteins/metabolism , Animals , Cell Line , Gene Expression Regulation, Developmental/drug effects , Heart Diseases/chemically induced , Heart Diseases/embryology , Humans , Peptides/adverse effects , Peptides/chemistry , Peptides/pharmacology , ZebrafishABSTRACT
The Drosophila heart, also referred to as the dorsal vessel, pumps the insect blood, the hemolymph. The bilateral heart primordia develop from the most dorsally located mesodermal cells, migrate coordinately, and fuse to form the cardiac tube. Though much simpler, the fruit fly heart displays several developmental and functional similarities to the vertebrate heart and, as we discuss here, represents an attractive model system for dissecting mechanisms of cardiac aging and heart failure and identifying genes causing congenital heart diseases. Fast imaging technologies allow for the characterization of heartbeat parameters in the adult fly and there is growing evidence that cardiac dysfunction in human diseases could be reproduced and analyzed in Drosophila, as discussed here for heart defects associated with the myotonic dystrophy type 1. Overall, the power of genetics and unsuspected conservation of genes and pathways puts Drosophila at the heart of fundamental and applied cardiac research.
Subject(s)
Disease Models, Animal , Drosophila/physiology , Heart Diseases/pathology , Heart/embryology , Aging/genetics , Animals , Gene Expression Regulation, Developmental , Heart Diseases/embryology , Heart Diseases/genetics , HumansABSTRACT
BACKGROUND: Nano-titanium dioxide (nano-TiO2) is amongst the most widely utilized engineered nanomaterials (ENMs). However, little is known regarding the consequences maternal ENM inhalation exposure has on growing progeny during gestation. ENM inhalation exposure has been reported to decrease mitochondrial bioenergetics and cardiac function, though the mechanisms responsible are poorly understood. Reactive oxygen species (ROS) are increased as a result of ENM inhalation exposure, but it is unclear whether they impact fetal reprogramming. The purpose of this study was to determine whether maternal ENM inhalation exposure influences progeny cardiac development and epigenomic remodeling. RESULTS: Pregnant FVB dams were exposed to nano-TiO2 aerosols with a mass concentration of 12.09 ± 0.26 mg/m3 starting at gestational day five (GD 5), for 6 h over 6 non-consecutive days. Aerosol size distribution measurements indicated an aerodynamic count median diameter (CMD) of 156 nm with a geometric standard deviation (GSD) of 1.70. Echocardiographic imaging was used to assess cardiac function in maternal, fetal (GD 15), and young adult (11 weeks) animals. Electron transport chain (ETC) complex activities, mitochondrial size, complexity, and respiration were evaluated, along with 5-methylcytosine, Dnmt1 protein expression, and Hif1α activity. Cardiac functional analyses revealed a 43% increase in left ventricular mass and 25% decrease in cardiac output (fetal), with an 18% decrease in fractional shortening (young adult). In fetal pups, hydrogen peroxide (H2O2) levels were significantly increased (~ 10 fold) with a subsequent decrease in expression of the antioxidant enzyme, phospholipid hydroperoxide glutathione peroxidase (GPx4). ETC complex activity IV was decreased by 68 and 46% in fetal and young adult cardiac mitochondria, respectively. DNA methylation was significantly increased in fetal pups following exposure, along with increased Hif1α activity and Dnmt1 protein expression. Mitochondrial ultrastructure, including increased size, was observed at both fetal and young adult stages following maternal exposure. CONCLUSIONS: Maternal inhalation exposure to nano-TiO2 results in adverse effects on cardiac function that are associated with increased H2O2 levels and dysregulation of the Hif1α/Dnmt1 regulatory axis in fetal offspring. Our findings suggest a distinct interplay between ROS and epigenetic remodeling that leads to sustained cardiac contractile dysfunction in growing and young adult offspring following maternal ENM inhalation exposure.
Subject(s)
Epigenesis, Genetic/drug effects , Heart Diseases/chemically induced , Maternal Exposure/adverse effects , Nanoparticles/toxicity , Prenatal Exposure Delayed Effects/chemically induced , Reactive Oxygen Species/metabolism , Titanium/toxicity , Animals , Female , Fetal Heart/cytology , Fetal Heart/drug effects , Fetal Heart/metabolism , Heart Diseases/embryology , Heart Diseases/metabolism , Male , Mice , Mice, Inbred Strains , Mitochondria, Heart/drug effects , Mitochondria, Heart/metabolism , Myocytes, Cardiac/drug effects , Myocytes, Cardiac/metabolism , Nanoparticles/administration & dosage , Pregnancy , Prenatal Exposure Delayed Effects/metabolism , Titanium/administration & dosageABSTRACT
INTRODUCTION: In intrauterine growth restriction (IUGR), increased uteroplacental vascular impedance contributes to preferential flow to left ventricle (LV), with consequent alteration of its compliance and increased left atrial (LA) pressure. Pulmonary vein pulsatility index (PVPI) reflects the increased impedance to LA filling and could be used as a cardiac monitoring parameter in IUGR. MATERIAL AND METHODS: A total of 27 IUGR fetuses (group 1), 28 fetuses with appropriate growth for gestational age from hypertensive mothers (group 2), and 28 controls (group 3) were studied. Pulsatility indices (PIs) of pulmonary veins and ductus venosus were calculated by Doppler echocardiography. Obstetric ultrasound was used to assess the PIs of uterine, umbilical, and middle cerebral arteries. Statistical analysis used analysis of variance, post-hoc Tukey, and Pearson's tests. RESULTS: Mean PVPI was higher in IUGR group (1.27 ± 0.39) when compared to groups 2 (1.02 ± 0.37; p = 0.01) and 3 (0.75 ± 0.12; p < 0.001). In group 2, moderate correlation between PVPI and ductus venosus pulsatility index (DVPI) was found but not between PVPI and cerebroplacental ratio (CPR). DISCUSSION: Higher PVPI in IUGR reflects decreased LV compliance and altered LA dynamics. As LV dysfunction precedes right ventricle, our results suggest that PVPI could be an early echocardiographic parameter of fetal diastolic function in IUGR.
Subject(s)
Fetal Growth Retardation/physiopathology , Hypertension, Pregnancy-Induced/diagnostic imaging , Placental Insufficiency/diagnostic imaging , Pulmonary Veins/physiopathology , Adult , Blood Flow Velocity , Echocardiography, Doppler , Female , Heart Diseases/complications , Heart Diseases/diagnostic imaging , Heart Diseases/embryology , Hemodynamics , Humans , Hypertension, Pregnancy-Induced/physiopathology , Middle Cerebral Artery/diagnostic imaging , Placental Insufficiency/physiopathology , Pregnancy , Pulsatile Flow , Ultrasonography, Prenatal , Umbilical ArteriesABSTRACT
Extensive studies have shown how bilateral symmetry of the vertebrate embryo is broken during early development, resulting in a molecular left-right bias in the mesoderm. However, how this early asymmetry drives the asymmetric morphogenesis of visceral organs remains poorly understood. The heart provides a striking model of left-right asymmetric morphogenesis, undergoing rightward looping to shape an initially linear heart tube and align cardiac chambers. Importantly, abnormal left-right patterning is associated with severe congenital heart defects, as exemplified in heterotaxy syndrome. Here, we compare the mechanisms underlying the rightward looping of the heart tube in fish, chick and mouse embryos. We propose that heart looping is not only a question of direction, but also one of fine-tuning shape. This is discussed in the context of evolutionary and clinical perspectives.
Subject(s)
Body Patterning , Heart Diseases/embryology , Heart/embryology , Animals , Humans , Models, Biological , Morphogenesis , Vertebrates/embryologyABSTRACT
Perfluorooctanoic acid (PFOA), a wide spread environmental pollutant, was associated with developmental cardiotoxicity in chicken embryo, while the underlying molecular mechanism had not been fully elucidated. In the current study, 2â¯mg/kg (egg weight) PFOA and/or 100â¯mg/kg (egg weight) l-carnitine were exposed to embryonic day zero (ED0) chicken embryo via air cell injection, and then bone morphogenic protein 2 (BMP2) silencing lentivirus or BMP2 recombinant protein were introduced into ED2 embryo. Electrocardiography and histological methods were utilized to assess the cardiac function and morphology in hatchling chickens, respectively. Consistent with previous results, 2â¯mg/kg PFOA exposure at ED0 significantly elevated heart rate and thinned right ventricular wall in hatchling chickens, while l-carnitine co-treatment reverted such changes. BMP2 silencing induced very similar changes in hatchling chicken hearts as PFOA exposure, while co-exposure of recombinant BMP2 protein alleviated PFOA-induced changes. l-carnitine exposure alleviated the BMP2-silencing induced changes as well. Western blotting revealed that PFOA exposure enhanced BMP2 expression and suppressed pSMAD1 expression in ED15 chicken embryo hearts, while both changes were reverted by l-carnitine co-exposure. Furthermore, silencing of BMP2 significantly increased the expression level of PPAR alpha in ED15 chicken embryo hearts, while silencing of PPAR alpha did not have significant impact on BMP2 expression. In conclusion, BMP2/pSMAD1 signaling participates in the PFOA-induced developmental cardiotoxicity in chicken embryo, which is likely located upstream of PPAR alpha for this particular endpoint. Protection of BMP2 signaling might contribute to l-carnitine mediated protection against PFOA-induced developmental cardiotoxicity.
Subject(s)
Bone Morphogenetic Protein 2/pharmacology , Caprylates/toxicity , Carnitine/pharmacology , Environmental Pollutants/toxicity , Fluorocarbons/toxicity , Heart Diseases/prevention & control , Heart/drug effects , Animals , Bone Morphogenetic Protein 2/genetics , Bone Morphogenetic Protein 2/metabolism , Cardiotoxicity , Chick Embryo , Cytoprotection , Gene Expression Regulation, Developmental , Gene Silencing , Heart/embryology , Heart/physiopathology , Heart Diseases/chemically induced , Heart Diseases/embryology , Heart Diseases/physiopathology , Heart Rate/drug effects , PPAR alpha/genetics , PPAR alpha/metabolism , Phosphorylation , Recombinant Proteins/pharmacology , Signal Transduction/drug effects , Smad1 Protein/genetics , Smad1 Protein/metabolism , Ventricular Function, Right/drug effects , Ventricular Remodeling/drug effectsABSTRACT
Cardiac etiologies of hydrops fetalis have been a topic of concern due to challenging perinatal management. The common cardiac etiologies leading to hydrops fetalis include structural cardiac anomalies, cardiac dysrhythmias, cardiac tumors, cardiomyopathy and myocarditis. The mechanisms of cardiogenic hydrops fetalis may be: 1) elevation of atrial pressure and volume overload, 2) decrease of cardiac output, and 3) development of congestive heart failure. The diagnosis of hydrops fetalis was usually made at 19-36 gestational weeks, when ultrasound is a highly effective diagnostic method. Intrauterine interventions for certain congenital heart defects, maternal transplacental or direct fetal medications and fetal pacing placement for cardiac arrhythmias, and fetal or postnatal tumor resections are important progressions of etiologic treatment for hydrops fetalis. Treatment strategies for hydrops fetalis per se are usually ultrasound-guided pericardiocentesis and feto-amniotic shunting, whereas reaccumulation may require further interventions in utero or postnatally. Hydrops fetalis often carries a poor prognosis, and mortality remains high. Current developments in the management of hydrops fetalis should encourage physicians to attempt further fetal interventions.
Subject(s)
Heart Diseases/embryology , Hydrops Fetalis/etiology , Arrhythmias, Cardiac/diagnosis , Arrhythmias, Cardiac/embryology , Arrhythmias, Cardiac/therapy , Delivery, Obstetric , Female , Heart Defects, Congenital/diagnosis , Heart Defects, Congenital/embryology , Heart Defects, Congenital/therapy , Heart Diseases/diagnosis , Heart Diseases/therapy , Heart Neoplasms/diagnosis , Heart Neoplasms/embryology , Heart Neoplasms/therapy , Humans , Hydrops Fetalis/diagnosis , Hydrops Fetalis/therapy , Infant, Newborn , Pregnancy , Pregnancy Trimester, Second , Pregnancy Trimester, Third , Prenatal DiagnosisABSTRACT
BACKGROUND: Myocardial dysfunction occurs in a variety of fetal disorders. Findings from adult cardiology, where n-terminal pro-B-type natriuretic peptide (nt-proBNP) is an established biomarker of left ventricular dysfunction have been extended to fetal life. Since fetal blood sampling is technically challenging we investigated amniotic fluid nt-proBNP for its suitability to diagnose fetal myocardial dysfunction. METHODS: Ultrasound, Doppler examination and echocardiography was applied to classify cases and controls. Amniotic fluid nt-proBNP to amniotic fluid total protein ratio was calculated and compared to the gestational age-dependent reference intervals. In a subset of cases, fetal and maternal plasma nt-proBNP levels were determined. RESULTS: Specimen from 391 fetuses could be analyzed (171 cases, 220 controls). There was a high correlation between amniotic fluid and fetal blood nt-proBNP levels (r = 0.441 for cases; r = 0.515 for controls), whereas no correlation could be detected between maternal and fetal (blood and amniotic fluid) nt-proBNP concentrations. Specificity and positive likelihood ratio of amniotic fluid nt-proBNP to amniotic fluid total protein ratio were high (0.97 and 4.3, respectively). CONCLUSION: Amniotic fluid nt-proBNP measurement allows diagnostic confirmation of fetal myocardial dysfunction. It may serve as a useful adjunct in addition and correlation to existing tests of myocardial function, particularly in the context of invasive fetal therapy, where access to the amniotic cavity is part of the procedure.
Subject(s)
Amniotic Fluid/metabolism , Heart Diseases/diagnosis , Natriuretic Peptide, Brain/metabolism , Peptide Fragments/metabolism , Biomarkers/metabolism , Case-Control Studies , Electrocardiography , Female , Fetal Blood/metabolism , Fetal Diseases/diagnosis , Gestational Age , Heart Diseases/diagnostic imaging , Heart Diseases/embryology , Humans , Natriuretic Peptide, Brain/blood , Peptide Fragments/blood , Pregnancy , Pregnancy, Multiple , Sensitivity and Specificity , Ultrasonography, Doppler/methods , Ultrasonography, Prenatal/methodsABSTRACT
BACKGROUND: Prenatal alcohol exposure may cause cardiac development defects, however, the underlying mechanisms are not yet clear. In the present study we have investigated the roles of histone modification by curcumin on alcohol induced fetal cardiac abnormalities during the development. METHODS AND RESULTS: Q-PCR and Western blot results showed that alcohol exposure increased gene and active forms of caspase-3 and caspase-8, while decreased gene and protein of bcl-2. ChIP assay results showed that, alcohol exposure increased the acetylation of histone H3K9 near the promoter region of caspase-3 and caspase-8, and decreased the acetylation of histone H3K9 near the promoter region of bcl-2. TUNEL assay data revealed that alcohol exposure increased the apoptosis levels in the embryonic hearts. In vitro experiments demonstrated that curcumin treatment could reverse the up-regulation of active forms of caspase-3 and caspase-8, and down-regulation of bcl-2 induced by alcohol treatment. In addition, curcumin also corrected the high level of histone H3K9 acetylation induced by alcohol. Moreover, the high apoptosis level induced by alcohol was reversed after curcumin treatment in cardiac cells. CONCLUSIONS: These findings indicate that histone modification may play an important role in mediating alcohol induced fetal cardiac apoptosis, possibly through the up-regulation of H3K9 acetylation near the promoter regions of apoptotic genes. Curcumin treatment may correct alcohol-mediated fetal cardiac apoptosis, suggesting that curcumin may play a protective role against alcohol abuse caused cardiac damage during pregnancy.
Subject(s)
Apoptosis/drug effects , Curcumin/pharmacology , Fetal Alcohol Spectrum Disorders , Heart Diseases , Histones/metabolism , Myocardium/metabolism , Acetylation/drug effects , Animals , Apoptosis Regulatory Proteins/metabolism , Female , Fetal Alcohol Spectrum Disorders/drug therapy , Fetal Alcohol Spectrum Disorders/metabolism , Fetal Alcohol Spectrum Disorders/pathology , Fetus/embryology , Fetus/pathology , Heart Diseases/drug therapy , Heart Diseases/embryology , Heart Diseases/pathology , Mice , Myocardium/pathology , PregnancySubject(s)
Cardiotocography/methods , Heart/embryology , Vectorcardiography/methods , Adult , Echocardiography , Electrodes , Female , Heart/diagnostic imaging , Heart/physiology , Heart/physiopathology , Heart Diseases/diagnosis , Heart Diseases/diagnostic imaging , Heart Diseases/embryology , Heart Diseases/physiopathology , Hospitals, Teaching , Humans , Netherlands , Pregnancy , Pregnancy Trimester, Second , Prenatal Diagnosis/methods , Prospective Studies , Signal Processing, Computer-Assisted , Ultrasonography, PrenatalSubject(s)
Cardiology/standards , Heart Defects, Congenital/diagnostic imaging , Heart Diseases/diagnostic imaging , Practice Guidelines as Topic , Ultrasonography, Prenatal/standards , Echocardiography, Three-Dimensional/methods , Echocardiography, Three-Dimensional/standards , Echocardiography, Three-Dimensional/trends , Gynecology/standards , Gynecology/trends , Heart Defects, Congenital/embryology , Heart Diseases/embryology , Humans , Internationality , Obstetrics/standards , Obstetrics/trends , Ultrasonography, Prenatal/methods , Ultrasonography, Prenatal/trendsABSTRACT
We report 3 cases of prenatal diagnosis of premature constriction of the ductus arteriosus after maternal benzydamine hydrochloride therapy (3-mg lozenges) in third-trimester pregnancies. In each case, fetal echocardiography revealed a dilated, hypocontractile right ventricle with severe tricuspid regurgitation and constriction of the ductus arteriosus. Although the effect of indomethacin and other nonsteroidal anti-inflammatory drugs on prenatal ductal constriction is well known, readily available over-the-counter nonsteroidal anti-inflammatory drugs such as benzydamine can have an equally deleterious effect and are best avoided in the third trimester of pregnancy.
Subject(s)
Benzydamine/adverse effects , Ductus Arteriosus/drug effects , Ductus Arteriosus/diagnostic imaging , Heart Diseases/chemically induced , Heart Diseases/diagnostic imaging , Ultrasonography, Prenatal/methods , Adult , Anti-Inflammatory Agents/adverse effects , Constriction, Pathologic/chemically induced , Constriction, Pathologic/diagnostic imaging , Female , Heart Diseases/embryology , Humans , Pregnancy , Self Medication/adverse effectsABSTRACT
Suboptimal intrauterine development has been linked to predisposition to cardiovascular disease in adulthood, a concept termed 'developmental origins of health and disease'. Although the exact mechanisms underlying this developmental programming are unknown, a growing body of evidence supports the involvement of epigenetic regulation. Epigenetic mechanisms such as DNA methylation, histone modifications and micro-RNA confer added levels of gene regulation without altering DNA sequences. These modifications are relatively stable signals, offering possible insight into the mechanisms underlying developmental origins of health and disease. This review will discuss the role of epigenetic mechanisms in heart development as well as aberrant epigenetic regulation contributing to cardiovascular disease. Additionally, we will address recent advances targeting epigenetic mechanisms as potential therapeutic approaches to cardiovascular disease.
Subject(s)
Epigenesis, Genetic , Gene Expression Regulation, Developmental , Heart Diseases/genetics , Heart/embryology , Morphogenesis/genetics , Animals , Cardiovascular Agents/therapeutic use , Chromatin Assembly and Disassembly , DNA Methylation , Epigenesis, Genetic/drug effects , Gene Expression Regulation, Developmental/drug effects , Genetic Markers , Genetic Predisposition to Disease , Genetic Therapy , Heart/growth & development , Heart Diseases/embryology , Heart Diseases/physiopathology , Heart Diseases/therapy , Humans , MicroRNAs/genetics , PhenotypeABSTRACT
The present article aims to highlight fetal cardiac interventions (FCIs) in terms of indications, strategies, and fetal prognoses. FCIs of the early years were predominantly pharmacological therapies for fetal arrhythmia or heart block. A transplacental transmission of therapeutic agents has now become the main route of pharmacological FCIs. There have been various FCI strategies, which can be categorized into three types: pharmacological, open FCIs, and closed FCIs. Rather than as a routine management for materno-fetal cardiac disorders, however, FCIs are only applied in those fetal cardiac disorders that are at an increased risk of mortality and morbidity and warrant an interventional therapy. Pharmacological FCIs have been well applied in fetal arrhythmias but require further investigations for novel therapeutic agents. The development of open FCI in humans is an issue for the long run. Closed FCIs may largely rely on advanced imaging techniques. Hybrid FCIs might be the future goal in the treatment of fetal heart diseases.
Subject(s)
Fetal Diseases/therapy , Fetal Therapies , Heart Diseases/therapy , Fetal Diseases/diagnosis , Fetal Diseases/etiology , Heart Diseases/diagnosis , Heart Diseases/embryology , Humans , PrognosisABSTRACT
As development proceeds from the embryonic to fetal stages, cardiac energy demands increase substantially, and oxidative phosphorylation of ADP to ATP in mitochondria becomes vital. Relatively little, however, is known about the signaling mechanisms regulating the transition from anaerobic to aerobic metabolism that occurs during the embryonic period. The main objective of this study was to test the hypothesis that adrenergic hormones provide critical stimulation of energy metabolism during embryonic/fetal development. We examined ATP and ADP concentrations in mouse embryos lacking adrenergic hormones due to targeted disruption of the essential dopamine ß-hydroxylase (Dbh) gene. Embryonic ATP concentrations decreased dramatically, whereas ADP concentrations rose such that the ATP/ADP ratio in the adrenergic-deficient group was nearly 50-fold less than that found in littermate controls by embryonic day 11.5. We also found that cardiac extracellular acidification and oxygen consumption rates were significantly decreased, and mitochondria were significantly larger and more branched in adrenergic-deficient hearts. Notably, however, the mitochondria were intact with well-formed cristae, and there was no significant difference observed in mitochondrial membrane potential. Maternal administration of the adrenergic receptor agonists isoproterenol or l-phenylephrine significantly ameliorated the decreases in ATP observed in Dbh-/- embryos, suggesting that α- and ß-adrenergic receptors were effective modulators of ATP concentrations in mouse embryos in vivo. These data demonstrate that adrenergic hormones stimulate cardiac energy metabolism during a critical period of embryonic development.
Subject(s)
Adrenergic Agents/pharmacology , Autonomic Nervous System Diseases/embryology , Autonomic Nervous System Diseases/physiopathology , Dopamine beta-Hydroxylase/deficiency , Dopamine beta-Hydroxylase/genetics , Energy Metabolism/drug effects , Energy Metabolism/genetics , Heart Diseases , Norepinephrine/deficiency , Adrenergic Agents/metabolism , Animals , Autonomic Nervous System Diseases/genetics , Autonomic Nervous System Diseases/metabolism , Dopamine beta-Hydroxylase/metabolism , Embryo, Mammalian , Epinephrine/metabolism , Epinephrine/pharmacology , Female , Heart/drug effects , Heart/embryology , Heart/innervation , Heart Diseases/embryology , Heart Diseases/genetics , Heart Diseases/metabolism , Isoproterenol/pharmacology , Maternal-Fetal Exchange/drug effects , Mice , Mice, Knockout , Norepinephrine/metabolism , Norepinephrine/pharmacology , Pregnancy , Up-Regulation/drug effectsABSTRACT
Numerous maternal (diabetes, preeclampsia) and fetal pathologies (uteroplacental dysfunction, hydrops, infection, congenital heart disease) can lead to cardiac dysfunction in the fetus. This includes increase of pre- and afterload, compression of the heart, myocardial damage, hypoxia and hyperglycemia. Beside already established methods like m-mode and pulse-waved Doppler, new promising technologies like tissue Doppler and speckle tracking are available for monitoring fetal cardiac function. Some of these new techniques have not been part of clinical routine yet because no validation has been performed so far and/or the technique is too time-consuming. Other technologies are currently being tested and only part of research projects. Innovations like speckle tracking that have its seeds in adult cardiology, are still limited because of the smallness of the fetal heart, the higher heart rate, fetal and maternal moving artefacts and finally because of a missing fetal ECG signal. Therefore their application should be performed critically.
Subject(s)
Elasticity Imaging Techniques/methods , Fetal Heart/diagnostic imaging , Heart Diseases/diagnosis , Heart Diseases/embryology , Heart Function Tests/methods , Image Enhancement/methods , Ultrasonography, Prenatal/methods , Fetal Heart/embryology , HumansABSTRACT
We verified the feasibility of telediagnosis of fetal disease by (i) grading telediagnosis by a pediatric cardiologist into five confidence levels; and (ii) comparison of fetal telediagnosis with hands-on fetal diagnosis or postnatal diagnosis. In 114 patients suspected of having heart disease (real time, n = 15; recorded image transmission, n = 99), 79 patients were in level 5 (excellent), 17 in level 4 (good), eight in level 3 (fair), 10 in level 2 (poor), and no patients in level 1 (bad). The average was 4.5, and in 96 patients (84% of all) telediagnosis was accurate (above 4), whereas in 18 patients it was inaccurate (level 2 or 3). In re-examination of 25 patients, telediagnosis was confirmed in patients in level 4 and 5, whereas heart disease was missed in patients in levels 2 or 3. The correct diagnosis matched the high confidence level of a specialist based on recognizable transmitted images.
Subject(s)
Fetal Diseases/diagnostic imaging , Heart Diseases/diagnostic imaging , Heart Diseases/embryology , Internet , Telemedicine , Ultrasonography, Prenatal , Feasibility Studies , Female , Humans , Pregnancy , Reproducibility of ResultsABSTRACT
With the advancement of transcriptome profiling by micro-arrays and high-throughput RNA-sequencing, transcriptome complexity and its dynamics are revealed at different levels in cardiovascular development and diseases. In this review, we will highlight the recent progress in our knowledge of cardiovascular transcriptome complexity contributed by RNA splicing, RNA editing and noncoding RNAs. The emerging importance of many of these previously under-explored aspects of gene regulation in cardiovascular development and pathology will be discussed.
Subject(s)
Heart Diseases/embryology , Heart/embryology , RNA Editing , RNA Splicing , RNA, Untranslated/metabolism , Transcriptome , Animals , Gene Expression Regulation, Developmental , HumansABSTRACT
OBJECTIVE: evaluate the relationship between impaired growth during intrauterine life and adult risk of cardiovascular disease and death. MATERIALS: review of the most important contributions to the relationship between intrauterine fetal life and heart disease insurgence in childhood and adulthood, starting with a schematic representation of the principal steps in human heart development, discussion of the new theory on the relevance of the number of cardiomyocytes that every heart shows at birth. RESULTS: intrauterine environment defines the epigenetic profile of newborns, with implications for the risk of developing diseases later in adult life. This means that the programming of cardiovascular risk and other pathologies, such as obesity, in adulthood takes place starting from intrauterine life. CONCLUSIONS: it can be hypothesized that by preventing and eventually treating cardiovascular diseases in the pediatric age, if these are already present in their early and/or in light forms, the long-term management of complications could be approached differently and more effectively than by postponing the treatment to adulthood. The future challenge in this fascinating field of clinical research is the discovery of the molecular mechanisms underlying the association between intrauterine growth restriction and fetal onset of adult cardiac disease, so as to make a dream come true by applying primary prevention of adult heart disease in the womb.